CRL Stock Analysis: Buy, Sell, or Hold?
CRL - Charles River Laboratories International, Inc.
$187.46
5.90 (3.25%)
▲
5d:
-0.54%
30d:
+18.0%
90d:
+18.64%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When CRL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRL shows positive signals but monitor for confirmation. Market pricing in 1.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: CRL shows positive signals but monitor for confirmation. Market pricing in 1.7% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$273.52
Based on 7.5% avg growth
INTRINSIC VALUE TODAY
$169.83
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CRL is currently trading at $187.46, which is considered slightly high relative to its 30-day fair value range of $162.02 to $189.00. The stock's valuation (Forward PE: 14.8) is in line with its historical norms (15.5). Remarkably, the market is currently pricing in an annual earnings decline of 1.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CRL is showing sideways momentum. Immediate support is located at $180.55, while resistance sits at $193.81. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $215.33 (+18.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRL is showing sideways momentum. Immediate support is located at $180.55, while resistance sits at $193.81. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $215.33 (+18.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$162.02 -
$189.00
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
67.6%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading below Wall St target ($215.33)
Trading Range Analysis
30-Day Trading Range
$162.02 -
$189.00
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$180.55
Resistance Level
$193.81
Current Trend
Sideways
Technical data as of
Jun 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.75
Wall Street Target
$215.33
(+18.6%)
Revenue Growth (YoY)
1.2%
Earnings Growth (YoY)
-17.3%
Profit Margin
-4.6%
Valuation Discount vs History
-1.7% cheaper
PE vs Historical
14.8 vs 15.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.7%
(market-implied from PE analysis)
1-Year Target
$178.47
(-2%)
2-Year Target
$175.44
(-3%)
3-Year Target
$172.46
(-5%)
3-Yr Target (if PE normalizes)
(PE: 15→16)
$181.21
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 11.0%)
$366.24
(+102%)
Base:
(SPY PE: 14.8, Growth: 11.0%)
$248.05
(+37%)
Bear:
(PE: 12.5, Growth: 11.0%)
$210.84
(+16%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.8 to 15.5
Stabilization Target:
$190.78
(+5.1%)
PE Expansion Potential:
+5.1%
Share & Embed Analysis
Last updated: June 23, 2026 12:56 PM ET
Data refreshes hourly during market hours. Next update: 1:56 PM
Data refreshes hourly during market hours. Next update: 1:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRL showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
NEUTRAL
Recent Transactions
Ro Khanna
BUY
2026-03-30
Ro Khanna
SELL
2026-02-05
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$599 | 55 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$142 | 56 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$242 | 51 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$260 | 62 BUY |
